LENZ Therapeutics (LENZ) news

LONZA upgrades organic growth model with mid term targets

Lonza has confirmed its mid-term strategic direction following a strong first-half performance in 2024, with the company maintaining its upgraded guidance for the 2024–2028 period. The Swiss-based contract development and manufacturing organization (CDMO) reported sales of CHF 3.1 billion in the…

Lenz Therapeutics, Inc.: BofA Global Research cuts to neutral from buy; cuts price objective to $7 from $31

Bank of America Global Research has revised its stance on Lenz Therapeutics, Inc. (Nasdaq: LENZ), downgrading the stock from "Buy" to "Neutral" and reducing its price target from $31 to $7 as of August 13, 2026. This adjustment follows a reassessment of the company’s growth trajectory, particularly…

CStone enters into commercialization pact with Arrotex

CStone Pharmaceuticals (HKEX: 2616) has not entered into a commercialization agreement with Arrotex for any of its drug candidates as of the latest available information. However, Arrotex Pharmaceuticals has recently entered into an exclusive license and commercialization agreement with LENZ…

Lenz Thera, Arrotx Pharma get license & commercialization pact

LENZ Therapeutics, Inc. (Nasdaq: LENZ) has entered into an exclusive license and commercialization agreement with Laboratoires Théa for the registration and commercialization of LNZ100 in Canada for the treatment of presbyopia. Under the terms of the agreement, LENZ is eligible to receive over $70…

Lenz Therapeutics - to receive upfront payment and profit share from Arrotex Vizz sales